NCT lookup

Inclusion criteria :

* Adult participants with a physician diagnosis of asthma for at least 12 months based on the Global Initiative for Asthma (GINA) 2017 Guidelines.
* Participants with existing treatment with medium to high dose ICS (greater than or equal to \[\>=\] 250 microgram (mcg) of fluticasone propionate twice a day (BID) or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or clinically comparable) in combination with a LABA as second controller for at least 3 months with a stable dose \>=1 month prior to Visit 1.
* Participants with pre-bronchodilator FEV1 greater than (\>) 40 percent (%) of predicted normal at Visit 1/Screening. Pre-bronchodilator FEV1 \>=50% but less than or equal to (\<=) 85% of predicted normal at Visit 2/Baseline.
* Participants with reversibility of at least 12% and 200 milliliters (mL) in FEV1 after administration of 2 to 4 puffs (200-400 microgram \[µg\]) of albuterol/salbutamol or levalbuterol/levosalbutamol during screening or documented history of a reversibility test that meets this criteria within 12 months prior to Visit 1 or documented positive response to methacholine challenge (a decrease in FEV by 20% \[PC20\] of less than \[\<\] 8 milligram per milliliter \[mg/mL\]) within 12 months prior to Visit 1/Screening is considered acceptable to meet this inclusion criterion.
* Participants had experienced, within 1 year prior to Visit 1, any of the following events at least once:
* Treatment with a systemic steroid (oral or parenteral) for worsening asthma.
* Hospitalization or emergency medical care visit for worsening asthma.
* Signed written informed consent.

Exclusion criteria:

* Participants \<18 years or \>70 years of age (i.e., have reached the age of 71 at the screening visit).
* Participants with body mass index (BMI) \<16.
* Chronic lung disease (for example, chronic obstructive pulmonary disease \[COPD\], or idiopathic pulmonary fibrosis \[IPF\]), which might impair lung function.
* History of life threatening asthma (i.e., severe exacerbation that required intubation).
* Co-morbid disease that might interfere with the evaluation of investigational medicinal product (IMP).
* Participants with any of the following events within the 4 weeks prior to their Screening Visit 1:
* Treatment with 1 or more systemic (oral and/or parenteral) steroid bursts for worsening asthma;
* Hospitalization or emergency medical care visit for worsening asthma.
* Asthma Control Questionnaire 5-question version (ACQ-5) score \<1.25 or \>3.0 at Visit 2/randomization. During the screening period, an ACQ-5 of up to \<=4 was acceptable.
* Anti-immunoglobulin E (IgE) therapy (e.g., omalizumab \[Xolair®\]) within 130 days prior to Visit 1 or any other biologic therapy (including anti interleukin-5 \[anti-IL5\] monoclonal antibodies \[mAb\]) or systemic immunosuppressant (e.g., methotrexate) to treat inflammatory disease or autoimmune disease (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) and other diseases, within 2 months or 5 half-lives prior to Visit 1, whichever was longer.
* Participants with a history of a systemic hypersensitivity reaction to a biologic drug.
* Participants on or initiation of bronchial thermoplasty within 2 years prior to Visit 1 or plan to begin therapy during the screening period or the randomized treatment period.
* Current smoker or cessation of smoking within the 6 months prior to Visit 1.
* Previous smoker with a smoking history \>10 pack-years.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

• Birmingham, Alabama, United States
• Long Beach, California, United States
• Los Angeles, California, United States
• Rolling Hills Estates, California, United States
• San Jose, California, United States
• Stockton, California, United States
• Colorado Springs, Colorado, United States
• Ann Arbor, Michigan, United States
• Minneapolis, Minnesota, United States
• Papillion, Nebraska, United States
• Edmond, Oklahoma, United States
• Medford, Oregon, United States
• Portland, Oregon, United States
• Dallas, Texas, United States
• Dallas, Texas, United States
• Plano, Texas, United States
• Murray, Utah, United States
• Milwaukee, Wisconsin, United States
• Buenos Aires, Argentina
• Caba, Argentina
• Caba, Argentina
• Caba, Argentina
• Mendoza, Argentina
• Quillota, Chile
• Santiago, Chile
• Santiago, Chile
• Santiago, Chile
• Santiago, Chile
• Santiago, Chile
• Talca, Chile
• + 41 more on CT.gov